TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
This study is a placebo-controlled factorial study, randomized to study drug (moxifloxacin
vs. ethambutol) and treatment frequency (daily vs. thrice weekly after an initial two weeks
of daily therapy) during the first two months of standard treatment (with isoniazid,
rifampin, and pyrazinamide) for sputum smear-positive pulmonary tuberculosis.
Phase:
Phase 2
Details
Lead Sponsor:
Centers for Disease Control and Prevention
Treatments:
Fluoroquinolones Isoniazid Moxifloxacin Norgestimate, ethinyl estradiol drug combination Pyrazinamide Rifampin